Skip to main content

Table 2 Survival (Life Table)

From: Mortality in patients treated with intravitreal bevacizumab for age-related macular degeneration

Beva-cizumab

Year

Entering Interval

Withdrawing during Interval

Exposed to Risk

Terminal Events

Proportion Terminating

Cumulative Proportion Surviving at End of Interval

No

0–1

10,756

3050

9231

517

.06

.94

 

1–2

7189

2336

6021

327

.05

.89

 

2–3

4526

1443

3805

219

.06

.84

 

3–4

2864

963

2383

124

.05

.80

 

4–5

1777

770

1392

73

.05

.76

 

5–6

934

611

629

32

.05

.72

 

6–7

291

285

149

6

.04

.69

Yes

0–1

5385

1527

4622

470

.10

.90

 

1–2

3388

1099

2839

238

.08

.82

 

2–3

2051

631

1736

168

.10

.74

 

3–4

1252

407

1049

99

.09

.67

 

4–5

746

313

590

63

.11

.60

 

5–6

370

249

246

21

.09

.55

 

6–7

100

96

52

4

.08

.51